UNSPSC 51363303: Tameridone

This classification denotes a sedative and hypnotic with the molecular formula C22H26N6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 74ATQ0K1LA, chemically known as 1h-purine-2,6-dione, 3,7-dihydro-7-(2-(4-(1h-indol-3-yl)-1-piperidinyl)ethyl)-1,3-dimethyl- but generally known as tameridone, which bears US NIH Compound Identifier 71304. European Medicines Agency schedules Tameridone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10819MIG.

UNSPSC 51363303 Tameridone is a Commodity code that nominally identifies a specific pharmaceutical product, but recent state and local solicitations tagged under this code actually cover a broader range of pharmaceutical procurement — naloxone, generic multi-source drugs, over-the-counter products, and direct-to-manufacturer prescription programs. The work being solicited includes product supply agreements, volume-based pharmaceutical distribution contracts, and pharmacy benefit program restructuring initiatives. Issuing bodies include state health and human services agencies, county public health departments, and multi-state cooperative purchasing alliances. The Texas Health and Human Services Commission, Minnesota Department of Administration (through the MMCAP cooperative), and Seminole County, Florida represent the jurisdictions active in recent opportunities under this code.

Recent activity spans Florida, Minnesota, and Texas. Seminole County posted an IFB in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and a two-year initial contract term plus one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with a March 26, 2026 deadline, targeting an effective date of July 1, 2026, and a two-year initial term. The Texas Health and Human Services Commission posted a Request for Information in April 2026 regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking vendor capabilities and market intelligence with no formal budget or timeline disclosed at the RFI stage. Vendors responding to these opportunities must meet FDA compliance, cGMP certification, DSCSA requirements, E-Verify authorization, drug-free workplace certification, and specified insurance thresholds including commercial general liability coverage.